Listed by the USPTO as HOWARD, ZACHARY C
Tech Center 1700 • Art Units: 1646 1674 1681 1797
This examiner grants 64% of resolved cases
HOWARD, ZACHARY C is a USPTO patent examiner in tech center 1700 and art unit 1646. The profile reports 968 resolved cases, an allowance rate of 63.9%, and a median of 1036 days to allowance. The interview lift is 37.7%, making examiner interviews a significant prosecution consideration in the available data.
The principal companies are Regeneron Pharmaceuticals Inc., Novartis AG, and Pharmazz Inc. The listed firms are MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP, and BLANK ROME LLP. Practitioners can use the record to align claim development and interview preparation with observed outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18278676 | FLUORESCENT BIOSENSORS AND METHODS OF USE FOR DETECTING CELL SIGNALING EVENTS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18251913 | ANTIBODY Fc VARIANTS | Final Rejection | Novartis AG |
| 18187242 | USE OF CANAKINUMAB | Non-Final OA | Novartis AG |
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | Non-Final OA | Novo Nordisk A/S |
| 18283887 | METHODS AND MATERIALS FOR TARGETING TUMOR ANTIGENS | Final Rejection | The Johns Hopkins University |
| 18031840 | CD47 BLOCKADE AND COMBINATION THERAPIES THEREOF FOR REDUCTION OF VASCULAR INFLAMMATION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18776820 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18026696 | THERAPEUTIC AGENTS AND USES THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18558013 | Lipid Nanoparticle Therapeutics that Evade the Immune Response | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18546384 | CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.9% of resolved applications examined by Zachary C Howard were allowed (968 resolved cases), compared with 40.9% across Art Unit 1646 over the last five years.
This examiner's interview lift is +37.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Zachary C Howard took 1,036 days on average from filing to allowance.
Zachary C Howard examines applications in Art Unit 1646 in Tech Center 1700 (Chemistry & Materials).
